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Abstract
Background: There is a documented increase of diabetes mellitus in Sub Saharan Africa, a region where
tuberculosis is highly endemic. Currently, diabetes mellitus is one of the recognised risk factors of tuberculosis. No
study has reported the magnitude of diabetes mellitus among tuberculosis patients in Uganda, one of the
countries with a high burden of tuberculosis.
Methods: This was a cross-sectional study conducted among 260 consenting adult patients with a confirmed
diagnosis of tuberculosis admitted on the pulmonology wards of Mulago national referral and teaching hospital in
Kampala, Uganda to determine the prevalence of diabetes mellitus and associated clinical factors. Laboratory
findings as well as the socio-demographic and clinical data collected using a validated questionnaire was obtained.
Point of care random blood sugar (RBS) testing was performed on all the patients prior to initiation of anti
tuberculosis treatment. Diabetes mellitus was diagnosed if the RBS level was ≥ 200mg/dl in the presence of the
classical symptoms of diabetes mellitus.
Results: The prevalence of diabetes mellitus among the admitted patients with tuberculosis was 8.5%. Only 5
(1.9%) patients with TB had a known diagnosis of diabetes mellitus at enrolment. Majority of the study participants
with TB-DM co-infection had type 2 diabetes mellitus (n=20, 90.9%).
At bivariate analysis, raised mean ALT concentrations of ≥80 U/L were associated with DM (OR-6.1, 95% CI 1.4-26.36,
p=0.032) and paradoxically, HIV co-infection was protective of DM (OR-0.32, 95% CI 0.13-0.79, P=0.016). The
relationship between DM and HIV as well as that with ALT remained statistically significant at multivariate analysis
(HIV: OR- 0.17 95%CI 0.06-0.51, p=0.002 and ALT: OR-11.42 95%CI 2.15-60.59, p=0.004).
Conclusion: This study demonstrates that diabetes mellitus is common among hospitalized tuberculosis patients in
Uganda. The significant clinical predictors associated with diabetes mellitus among tuberculosis patients were HIV
co-infection and raised mean serum alanine transaminase concentrations.
Background
In 2011, the International Diabetes Federation (IDF) esti-
mated that about 366 million people worldwide have dia-
betes mellitus (DM). 80% of these people live in the low
and middle income countries where tuberculosis (TB) is
highly prevalent [1]. According to the World Health
Organisation (WHO), there were an estimated 8.8 million
incident cases of TB globally in 2010 [2].
Currently, both TB and DM are of great public health
importance globally especially in Sub Saharan Africa
(SSA) due to the converging epidemics of both commu-
nicable and non communicable diseases. With a preva-
lence rate of TB of 193/100,000 in 2010, Uganda is one
of the high burden TB countries in SSA [3]. There is
also an observed trend of increasing prevalence of DM
in Uganda. The estimated prevalence according to the
International Diabetes Federation in 2010 was 2.2% [4].
Recent evidence advocates for bi-directional screening
and care of TB and DM patients. This is because both
morbidities adversely affect each other [5] and currently,
there is plausible evidence from different studies to
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support the strong association between DM and TB
[6,7]. Diabetic patients have impaired cell mediated immu-
nity, renal failure, micronutrient deficiency and pulmonary
microangiopathy, all of which increase their propensity to de-
velop TB [8]. DM is also known to alter the clinical presenta-
tion of TB and its outcomes in terms of delayed sputum/
culture conversion, case fatality and treatment failure [9].
TB co-infection is associated with poor glycemic
control among DM patients. Reactionary hyperglycemia
often accompanies chronic infections like TB due to the
increased pro-inflammatory state and release of counter-
regulatory stress hormones like epinephrine, cortisol and
glucagon that are antagonistic of insulin [10]. Rifampi-
cin, a very potent anti TB drug has also been shown to
induce a transient early phase hyperglycemia owing to
augmentation of intestinal glucose absorption [11].
This study sought to determine the prevalence of
DM and the associated clinical factors among the
adult TB patients admitted on the pulmonology wards




Mulago national referral and teaching hospital is located in
Kampala, the capital city of Uganda and serves a population
of about 2 million people. It is a 1,500 bed facility serving
as a national referral hospital and teaching hospital for
Makerere University College of Health Sciences, Uganda.
The hospital has two adult pulmonology wards primarily
for admission of patients with the varied pulmonary me-
dical conditions like TB.
Study methods
This was a cross sectional study in which adult patients
with a confirmed diagnosis of TB admitted on the
pulmonology wards of Mulago hospital were consecu-
tively recruited during weekdays of the study period of
September 2011 up to February 2012.
Patients enrolled into the study were ≥18 years of age,
admitted on the pulmonology wards during the study
periods and had a confirmed diagnosis of TB. All pa-
tients who were on anti TB drugs and those who could
not offer informed consent were excluded from the
study.
A confirmed diagnosis of TB was made if the patient
presented with clinical symptoms suggestive of TB and
at least one of the following: a positive sputum smear
on Ziehl Nielsen or flourochrome (Auramine-O) stain
for acid fast bacilli (AFB), a positive Xpert/RIF-TB test
result, a positive sputum culture for TB and a histo-
logical diagnosis of TB on lymph node or pleural biopsy.
Data collection
All patients gave informed consent prior to enrolment
into the study. Information on the socio-demographic
characteristics, medical history and laboratory variables
of the consented eligible study participants was collected
using pre-coded questionnaire forms. All patients under-
went anthropometric measurements for estimation of
the body mass index (BMI).
A capillary blood sample was obtained for measure-
ment of the random blood sugar (RBS) level using a One
Touch UltraW glucometer from Johnson and Johnson
Company, United Kingdom. Blood was also drawn for
measurement of the serum albumin, renal function tests
(serum urea and creatinine) for calculation of the glo-
merular filtration rate (GFR), liver function tests (alanine
transaminase (ALT) and alkaline phosphatase (ALP)
levels), HIV serology and CD4 counts. The normal values
for the above tests were: serum albumin: 35–50 g/L, GFR:
90–120 ml/min/1.73 m [2], ALT: 0-80U/L and ALP:
30–129 U/L. All the above tests were done prior to initi-
ation of anti TB drugs. The cockroft Gault formula
below was used to estimate the glomerular filtration rate
(GFR). Normal GFR was defined as an estimated GFR of
≥ 90 ml/min/1.73 m [2].
GFR = [(140-Age in years) × body weight in kg/ serum
creatinine in mg/dl × 72] × 0.85 if female.
The diagnosis of DM was made basing on the recent
American Diabetes Association (ADA) guidelines of a
random or casual blood sugar level ≥ 200mg/dl in the
presence of the classical symptoms of DM [12]. The
classical symptoms of DM include: polyuria, polydipsia,
polyphagia, generalised body weakness and progressive
weight loss. Type 2 diabetic patients were defined as
patients aged ≥30 years on oral hypoglycaemic drugs
and/or insulin therapy while type 1 diabetic patients
were those aged < 30 years on insulin monotherapy.
Statistical analysis
Data was entered into EPI-INFO Version 6 and analysed
using SPSS version 14. Patient’s characteristics were
summarised with proportions and the continuous vari-
ables expressed in mean and standard deviation for
normally distributed variables.
To determine associations between the different fac-
tors and RBS levels, the outcome variable, bivariate
analyses using chi-square test was performed. For vari-
ables in which the cell values were less than 5, the
Fischer’s exact test was used instead. Continuous vari-
ables were categorised into 2 groups based on the nor-
mal cut off values and then compared. Age was
categorised into 2 groups using the cut of value of the
average age.
Binary logistic regression analysis was performed to
determine which factors were independently associated
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with DM among the study participants. Multivariate
analysis was then performed and variables considered
were those which had a conservatively set cut off p-value
of <0.3 on bivariate analysis. A p-value of <0.05 and confi-
dence intervals not including 1 were considered to be sta-
tistically significant.
Using the prevalence of 13.2% of DM among TB pa-
tients in Indonesia [13], with 80% power and a two-
sided α < 0.05, a sample size of 176 study subjects was
obtained. However, we enrolled 260 patients for the
study.
Ethical consideration
This study was approved by the department of Internal
Medicine, Makerere College of Health Sciences and the
Makerere University School of Medicine research and
ethics committee, Uganda.
Results
Socio-demographic, clinical and laboratory characteristics
of the patients
Of the 260 study participants enrolled, majority were male
(n=146, 56.2%). The mean age of the study participants was
34.5 years (S.D 9.5). The youngest participant was 18 years
and the eldest was 65 years. HIV co-infection was docu-
mented in 280 (80%) participants with 78% of them having
CD4 counts < 200 cells/mm [3]. The mean BMI was 17.4
kg/m [2]. Sixty three (23.2%) and 197 (75.8%) participants
had extra pulmonary TB (EPTB) and pulmonary TB (PTB)
respectively. Fifty (19.2%) of the participants had TB relapse
(Tables 1 and 2).
Prevalence of DM and the clinical characteristics of the
TB-DM co-infected participants
DM was diagnosed in 22 study participants giving a
prevalence of 8.5%. Twenty participants had type 2 DM
Table 1 Baseline socio-demographic factors and clinical characteristics of the study participants
Characteristic Frequency (n=260) Percentage (%)




Gender Male 146 56.2
Female 114 43.8
Place of residence Rural 77 29.6
Urban 183 70.4
Level of education No formal education 18 6.9
Primary level 168 64.6
Secondary level 54 20.8
Tertiary level 20 7.7
Occupation Unemployed 58 22.3
Self employed 34 13.1
Unskilled 147 56.5
Skilled 21 8.1
Smoking status Former smokers 66 25.4
Non smokers 194 74.6
HIV infection Positive 208 80
On HAART Yes 61 29
Known diabetes mellitus Yes 5 1.9
History of TB treatment. No 207 79.6
Karnofsky score (%) Mean (SD) 61.5 (14.3)
<70% 132 50.8
Category of TB PTB 197 75.8
Body mass index, kg/m2 Mean (SD) 17.4 (2.5)
<18.5 181 69.6
* SD- Standard deviation.
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while 2 had type 1 DM. Of the 22 participants, 5 (22.7%)
had a known diagnosis of DM and all had poor glycemic
control (defined as RBS level > 180 mg/dl) at baseline
despite being on glucose lowering therapy. The back-
ground prevalence of DM on the medical units in the
hospital during the study period was 6.4%.
The most frequent symptoms among the study partici-
pants with DM-TB co-infection were polyuria (90.9%),
polydipsia (77.3%) and progressive weight loss (68.2%).
The socio-demographic characteristics, category and epi-
sode of TB of the study participants did not significantly
differ between the diabetic and non diabetic TB patients
(Table 3).
At bivariate analysis, HIV co-infection was protective of
DM (OR-0.32, 95% CI 0.13-0.79, P=0.016) and raised
mean ALT concentrations were associated with DM
(OR-6.1, 95% CI 1.4-26.36, p=0.032). For every unit
change in the ALT category there was a 1.8 unit increase
in the RBS (95% CI 0.35-3.3, p=0.02).
The relationship between DM and HIV as well as that
with ALT remained statistically significant on multiva-
riate analysis (HIV: OR- 0.17 95%CI 0.06-0.51, p=0.002
and ALT: OR-11.42 95%CI 2.15-60.59, p=0.004). On
multivariate analysis, for every unit change in the ALT
category, there was a 2.4 unit change in the random
blood sugar (95%CI=0.77-4.1, p=0.04). Other variables
considered in the multivariate analysis included age, sex,
episode of TB infection (relapse or new infection), BMI,
category of TB and smoking, though were not statisti-
cally significant.
The diabetic TB-HIV co-infected patients had lower
baseline mean CD4 counts compared to non diabetic
TB-HIV co-infected patients, although this was not sta-
tistically significant (Table 4).
Discussion
This study demonstrates that DM is highly frequent among
admitted TB patients in Mulago hospital, Uganda. To our
knowledge, this is the first study to examine this association
in Uganda, one of the high burden TB countries in SSA.
The reported prevalence of DM among the TB patients of
8.5% is significantly higher than the estimated prevalence
of DM among the general population in Uganda (2.2%) [4]
and the back ground prevalence of DM on the medical
units in the hospital during the study period (6.4%).
The documented prevalence of DM among TB patients
in the African studies published between 1980 and 2006
varies between 2.1%-6.7% [14-17]. The observed preva-
lence of DM among TB patients in our study is compar-
able to that reported from Nigeria [16] and Tanzania [17]
but higher than what was noted in South Africa [14] and
Guinea Conakry [15].
This heterogeneity in the above results could probably
be explained by the varied techniques used to diagnose
DM among the TB patients and the probable effects of
co morbidities like HIV. Largely, an oral glucose toler-
ance test (OGTT) was used in diagnosing DM in most
African studies [14,16,17]. Balde et al. used a fasting ca-
pillary blood test to diagnose DM among TB patients in
Guinea Conakry [15]. In our study, the diagnosis of DM
was made basing on a random or casual capillary blood
test. No particular method of diagnosing DM among TB
patients has been advocated for. Either a random blood
sugar (RBS), fasting blood sugar (FBS), OGTT or gly-
Table 2 Laboratory findings of the study participants
Laboratory characteristic Frequency (n=260) Percentage (%)




Mean (SD) 126.8 (161.8)
<200 163 78.4
**ALT level (U/L) NR in U/L (0–80)
Mean (SD) 17.4 (25.7)
≥80 9 3.5
***ALP level (U/L) NR in U/L (30–129)
Mean (SD) 160.9 (140.3)
≥129 109 41.9
****GFR (ml/min/1.73m2) NR in ml/min/1.73m2 (90–120)
Mean (SD) 86.3(26.1)
<90 69 26.5
* SD- Standard deviation NR- Normal range **ALT- Alanine transaminase *** ALP- Alkaline phosphatase ****GFR-Glomerular filtration rate.
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Table 3 Bivariate analysis for the characteristics of the study participants
Random Blood Sugar (RBS) level in mg/dl
Characteristic ≥200, (n=22) n (%) <200, (n=238) n (%) OR 95%CI P value
Age in years
Age≥35 17(6.5) 160(61.5) 1.66(0.59-4.66) 0.33
Age<35 5(1.9) 78(0.3)
Gender
Male 9(40.9) 137(57.6) 0.51(0.21-1.24) 0.13
Female 13(59.1) 101(42.4
Place of residence
Urban 15(68.2) 168(70.6) 0.89(0.35-2.28) 0.813
Rural 7(31.8) 70(29.4)
Occupation
Employed 17(77.3) 185(77.7) 0.97(0.34-2.76) 0.961
Unemployed 5(22.7) 53(22.3)
Smoking status
Former smoker 3(13.6) 63(26.5) 2.28(0.65-7.97) 0.141
Non smoker 19(86.4 175(73.5)
HIV serology
HIV positive 13(59.1) 195(81.5) 0.32(0.13-0.79) 0.016
HIV negative 9(40.9) 43(18.5)
Category of TB
δPTB 19(86.4) 178(74.8) 0.46(0.13-1.64) 0.225
§EPTB 3(13.6) 60(25.2)
Episode of TB
Newly diagnosed 18 (81.8) 192 (80.7) 2.13(0.61-7.5) 0.3
Relapsed TB 4(18.2) 46(19.3)
*BMI, kg/m2
≥17.5 7(2.6) 103(39.6) 0.61(0.24-1.6) 0.3
<17.5 15(5.7) 135(51.9)
**GFR,ml/min
GFR<90 5 64 1.25(0.44-3.53) 0.67
GFR≥90 17 174
***ALT in U/L






ALP≥12 8 102 0.76(0.31-1.88) 0.56
ALP<129 14 136
SD- Standard deviation *BMI-Body mass index ** GFR-Glomerular filtration rate ***ALT- Alanine transaminase **** ALP- Alkaline phosphatase δPTB-Pulmonary
tuberculosis §EPTB-Extra pulmonary tuberculosis.
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cated haemoglobin (HbA1c) test can be used alone or in
combination [5].
Similar studies from other parts of the world have
reported remarkably higher prevalence of DM among
TB patients. In Asia and the Middle East, the docu-
mented prevalence varies from 9.5%-44% [13,18-23] and
11.9%-27% [24-26] respectively. A multi centre study
done in Texas, USA and Mexico reported prevalence of
39% and 36% respectively [27]. This higher prevalence
could probably be due to the higher background preva-
lence of DM in the general population in those respec-
tive countries.
Type 2 DM was the most frequent type of DM encoun-
tered among the study participants with DM-TB
co-infection (90.9%). A similar observation has been docu-
mented in most similar studies [13,15,18]. This could
probably be due to the higher proportions of people with
type 2 DM compared to type 1 DM in most general
populations.
Five (1.9%) of the study participants at enrolment
had a prior diagnosis of DM and on assessment to de-
termine the extent of glycemic control, they all had
poor glycemic control which we defined as a RBS level
≥ 180 mg/dl. TB infection is often associated with a tran-
sient stress induced hyperglycemia which results into
suboptimal glycemic control among diabetic patients. It
usually resolves following TB therapy [28].
This form of reactionary hyperglycemia can also lead
to over diagnosis of DM among TB patients. Studies by
Alisjahbana et al. [13], Oluboyo et al. [16] and Mugusi
et al. [17] demonstrated improvement in the glycemic
status of some patients following TB treatment. How-
ever in our study, we did not perform a repeat assess-
ment of the glycemic status among the newly diagnosed
DM patients during the course of TB therapy.
HIV co-infection and raised mean serum ALT concen-
trations were noted to be independently associated with
DM among TB patients in our study. In contrast to avai-
lable literature and findings from other studies [29-33],
HIV infection appeared protective in our study. A prob-
able explanation for this is that most of our HIV positive
patients were taking cotrimoxazole prophylaxis, a drug
which has been found to cause hypoglycaemic effects in
some patients [34]. However, this relationship between
HIV and DM in our study needs to be interpreted with
caution. This is because a study done in this similar set-
ting to determine glycemic levels in patients with severe
sepsis (80% of whom also had HIV infection and were
on cotrimoxazole prophylaxis) revealed no statistically
significant association between HIV infection and hyper-
glycemia (OR-0.97, 95%CI 0.57-1.62) [35].
Raised mean serum ALT concentrations in TB/DM pa-
tients have not been described in any similar studies.
However, since majority of the study participants had
HIV co-infection, an elevated mean ALT concentration
of >66 U/L prior to diagnosis of DM was noted to be
significantly associated with DM among HIV infected
patients in one case control study performed in an urban
HIV clinic in the USA [33].
A raised mean serum ALT concentration is a strong
predictor of insulin resistance [36]. It also principally re-
flects direct hepatocellular damage or liver dysfunction.
Liver dysfunction secondary to underlying hepatitis C
and hepatosteatosis have been demonstrated to be asso-
ciated with DM [37-40].
Hepatitis C infection is associated with insulin resistance
owing to an increased pro-inflammatory state and produc-
tion of cytokines especially tumour necrosis factor α and
interleukin 6. These inhibit transcription of the glucose
transporter-4 and peroxisome proliferator –activated recep-
tor γ. Insulin resistance results into alteration in lipid me-
tabolism and deposition in the hepatocytes. Hepatosteatosis
often develops later. Hepatitis C co-infection is also associ-
ated with autoimmune pancreatic beta cell damage leading
to DM [37-40]. In addition to hepatitis C infection, human
herpes virus type 8 (HHV-8), a highly prevalent virus
among HIV infected patients that causes with kaposi
sarcoma has also been demonstrated to be linked to ketosis
prone type 2 DM, an atypical form of DM commonest
among black Africans [41]. In our study however, we did
not assess for presence of hepatosteatosis, hepatitis C or
HHV-8 co-infection among the study participants.
Majority of the similar studies have reported increasing
age, overweight or obesity [15,19,20,27] and male gender
Table 4 Predictor variables considered for association with DM at multivariate analysis
Characteristic Crude OR 95% CI P value Adjusted OR 95% CI P value
HIV sero-status 0.32 (0.13-0.79) 0.016 0.17 (0.06-0.51) 0.002
ALT in U/L 6.10 (1.4-26.36) 0.032 11.42 (2.15-60.59) 0.004
Gender 0.51 (0.21-1.26) 0.14 0.52 (0.17-1.55) 0.242
Smoking 2.28 (0.65-7.97) 0.14 2.64 (0.57-12.2) 0.214
TB category 0.46 (0.13-1.64) 0.225 0.56 (0.16-1.94) 0.36
TB episode 2.13 (0.61-7.5) 0.31 0.73 (0.48-7.4) 0.36
BMI 0.61 (0.24-1.6) 0.3 0.59 (0.21-1.64) 0.314
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[20] as the clinical factors associated with DM among TB
patients. Sedentary lifestyle and family history of DM and
obesity were also noted to be independently associated
with DM in the study done in Guinea Conakry [15]. These
clinical factors were not significantly associated with DM
among our study participants.
Study limitations
We acknowledge important limitations in our study. Only
one RBS estimation was used to diagnose DM hence lead-
ing to a possibility of overestimating of the prevalence of
DM among our study participants since patients with
reactive hyperglycemia could have been included. Use of
an OGTT could have diagnosed more patients with bor-
derline DM.
Although the study adjusted for some of the con-
founding factors, the role of residual confounding factors
for the association between DM and TB cannot be ruled
out. In addition, due to the cross sectional nature of the
study, the temporality between the TB and DM could not
be ascertained.
As similar findings have been documented among TB
patients in other parts of the world, we believe that our
findings are generalisable and hence we recommend that
patients diagnosed with TB should routinely have their
blood sugar levels assessed in order to enable timely
diagnosis and optimal management of DM.
Conclusion
DM is a frequent co morbid condition among TB patients
in Uganda. HIV co-infection and raised mean serum ALT
concentrations are independently associated with DM
among TB patients. We recommend routine screening for
DM among TB patients in Uganda especially those with
raised mean serum ALT concentrations of ≥80 U/L. Fur-
ther prospective studies to examine the effects of DM on
the clinical outcomes among TB-DM co-infected patients
in Uganda are warranted.
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